Core Insights - WORK Medical Technology Group LTD has entered into an investment agreement to acquire a 10% equity interest in Neologics Bioscience Inc. for US$1 million, enhancing its strategic focus on innovation and collaboration in medical technology [1][3] Investment Details - The investment will increase Neologics's total capital reserve to US$10 million, with existing shareholders retaining a 90% ownership interest [1] - WORK Medical will have corporate governance rights corresponding to its 10% equity interest, including rights to nominate board members and a right of first refusal for future equity interests [1] Use of Proceeds - The investment proceeds are intended to support Neologics's operations, research and development, market expansion, talent acquisition, and other legitimate business purposes [2] Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, with a diverse product portfolio of 21 products sold in 34 provincial-level regions in China and over 30 countries worldwide [4] - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [4]

Core Points - WORK Medical Technology Group LTD will implement a reverse stock split of its ordinary shares on a 1-for-100 basis, effective October 21, 2025 [1][2] - The reverse stock split aims to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) regarding the minimum bid price per share [2] - The total number of outstanding Class A ordinary shares will decrease from approximately 96 million to about 960,000, and Class B ordinary shares will reduce from approximately 7.59 million to around 76,000 [4] Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, including disposable medical devices [5] - The company has a diverse product portfolio of 21 products, including customized masks, and has sold products in 34 provincial-level regions in China and over 30 countries globally [5] - WORK Medical has received various quality-related manufacturing designations and has registered 17 products with the U.S. FDA for entry into the U.S. market [5]

Core Points - WORK Medical Technology Group LTD has received a determination letter from Nasdaq regarding the delisting of its Class A ordinary shares due to a closing bid price of $0.10 or less for ten consecutive trading days [1][2] - The trading of the Company's Class A ordinary shares will be suspended on October 20, 2025, unless an appeal is filed [2] - The Company plans to appeal the delisting determination by October 16, 2025, which will stay the suspension pending the Panel's decision [3] Company Overview - WORK Medical Technology Group LTD is a supplier of medical devices in China, operating through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. [5] - The Company develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products, including customized masks and medical consumables [5] - The products are sold in 34 provincial-level regions in China and in over 30 countries worldwide, with 17 products registered with the U.S. Food and Drug Administration [5] Compliance and Future Actions - The Company is considering all available options to regain compliance with Nasdaq Listing Rules, including the possibility of implementing a reverse share split [4]

Core Points - WORK Medical Technology Group LTD has received an additional 180-calendar-day period from Nasdaq to regain compliance with the minimum bid price requirement [1][3] - The initial notice from Nasdaq indicated that WORK Medical's stock had failed to meet the minimum bid price requirement for 30 consecutive business days, leading to an initial compliance period that expired on October 6, 2025 [2] - To regain compliance, WORK Medical's stock must achieve a minimum closing bid price of $1.00 per share for at least 10 consecutive business days during the additional compliance period [4] Company Overview - WORK Medical Technology Group LTD, through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd., is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices [5] - The company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks, and has sold products in 34 provincial-level administrative regions in China and over 30 countries worldwide [5] - WORK Medical has received various quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [5]

Core Viewpoint - Univest Securities, LLC has successfully closed a $2.9 million registered direct offering for WORK Medical Technology Group LTD, a medical device supplier in China [1][3]. Group 1: Offering Details - The offering involved the sale of 38,999,334 Class A ordinary shares at a purchase price of $0.075 per share [2]. - The gross proceeds from the offering were approximately $2.9 million [3]. - The offering was conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on September 15, 2025 [4]. Group 2: Company Overview - WORK Medical Technology Group LTD develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products, including customized masks and medical consumables [7]. - The company has sold products in 34 provincial-level regions in China and has a presence in over 30 countries worldwide [7]. - WORK Medical Technology has received quality-related manufacturing designations and has registered 17 products with the U.S. FDA, allowing entry into the U.S. market [7]. Group 3: Univest Securities Overview - Univest Securities, LLC has been registered with FINRA since 1994 and provides a variety of financial services, including investment banking and advisory [6]. - The firm has raised over $1.3 billion in capital for issuers globally since 2019 and completed approximately 100 transactions across various industries [6].

Core Viewpoint - WORK Medical Technology Group LTD has entered into a strategic cooperation agreement with the Hong Kong Web3.0 Standardization Association to promote innovation in the Real-world Asset (RWA) sector through resource sharing and complementary strengths [1][4]. Group 1: Strategic Cooperation Agreement - The agreement focuses on collaboration in blockchain solutions, including asset tokenization, equity investment, and RWA technology development [4][5]. - WORK Medical will leverage its capital resources and expertise in medical device manufacturing alongside the Association's resources to advance asset tokenization [4]. - The partnership aims to integrate industrial and financial resources for co-investments to accelerate RWA market expansion [4]. Group 2: Association's Role and Objectives - The Hong Kong Web3.0 Standardization Association is dedicated to supporting the growth of Hong Kong's Web3.0 ecosystem through standardization and research [6]. - The Association's initiatives include promoting technological advancement, establishing standards, and enhancing public awareness of Web3.0 [6]. - The Association launched an RWA registration platform in August 2025 to further its mission [6]. Group 3: Company Profile - WORK Medical develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products sold in 34 regions in China and over 30 countries worldwide [8]. - The company has received quality-related manufacturing designations and has registered 17 products with the U.S. FDA for market entry in the U.S. [8].

Core Viewpoint - WORK Medical Technology Group LTD has signed a strategic cooperation agreement with Xin Rui Hospital to develop AI-driven medical products, aiming to enhance the digital healthcare ecosystem in China [1][2][4]. Group 1: Agreement Details - The agreement involves Work Hangzhou supporting Xin Rui Hospital in advancing hospital informatization and the application of AI-powered medical products [2]. - The collaboration aims to integrate AI technology with various medical resources at Xin Rui Hospital, including text, imaging, and laboratory data, to create a digital knowledge base for intelligent healthcare [2]. - The partnership is expected to enhance the development and clinical application of AI models across multiple healthcare scenarios, focusing on data governance, model training, and translating research into clinical practice [2]. Group 2: Company Background - WORK Medical Technology Group LTD, through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd., develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 items [5]. - The company has products sold in 34 provincial-level regions in China and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [5]. Group 3: Leadership Perspective - The CEO of WORK Medical expressed enthusiasm about the partnership, highlighting the goal of establishing a model for hospital digitalization and intelligent healthcare applications [4]. - The collaboration is anticipated to accelerate AI transformation in domestic hospitals and broaden the adoption of technology solutions [4].

Core Viewpoint - WORK Medical Technology Group LTD is conducting a registered offering of 10,000,000 ordinary and pre-funded units to raise funds for various corporate purposes, including upgrading production equipment and R&D investments [1][3]. Group 1: Offering Details - The offering price is set at $0.50 per Ordinary Unit and $0.4995 per Pre-funded Unit [1]. - Each Ordinary Unit includes one Class A ordinary share, one Series A warrant, and one Series B warrant, while each Pre-funded Unit consists of one pre-funded warrant, one Series A warrant, and one Series B warrant [2]. - The Company expects to receive gross proceeds of $5.0 million from the offering before deducting expenses [3]. Group 2: Use of Proceeds - Proceeds will be allocated for upgrading production equipment, investing in R&D, hiring experienced employees for compliance improvements, and general corporate purposes [3]. Group 3: Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, with a diverse product portfolio of 21 products [6]. - The Company has sold products in 34 provincial-level regions in China and in over 30 countries globally, with 17 products registered with the U.S. FDA [6].

Core Viewpoint - WORK Medical Technology Group LTD has announced a strategic partnership with Shanghai Chartwell Medical Device Co., Ltd to enhance growth and innovation in the healthcare sector [1][2]. Company Overview - WORK Medical Technology Group LTD is a supplier of Class I and II medical devices, with a diverse product portfolio of 21 products, including customized masks and medical consumables, sold in 34 provincial-level regions in China and over 30 countries globally [3]. - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. FDA, allowing entry into the U.S. market [3]. Partnership Details - The collaboration will involve Chartwell Medical's subsidiaries, including Fuying and Fufeng, focusing on mutual growth and unlocking new opportunities [2]. - The partnership aims to enhance operational efficiency, market leadership, and international competitiveness, with a goal to advance high-end medical technologies [2]. - Specific cooperation projects are expected to enrich WORK Medical's product portfolio and increase the proportion of high-value-added products, leading to substantial growth in revenue and profits over the next three years [2]. Strategic Initiatives - The partnership will explore joint investment funds to align industrial and financial resources, including potential investments in Chartwell Medical or merging it into WORK Medical [6]. - Future co-investments are planned in key projects such as healthcare infrastructure, advanced technology R&D, and global acquisitions [6]. Chartwell Medical Overview - Shanghai Chartwell Medical Device Co., Ltd specializes in high-end medical devices and consumables, serving the Asia-Pacific region with a diverse portfolio across multiple categories [4]. - The company holds exclusive agency rights for several leading high-end medical brands from Japan, enhancing its market position [4].